Clinical Trials Browser

Phase 1/2 × INDUSTRY × monalizumab × Clear all

NCT02643550 2023-05-12

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1/2 Completed

Head and Neck Neoplasms

NCT02557516 2019-12-17

Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL

Phase 1/2 Terminated

22 enrolled 16 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell